Back

Positive Modulators of N-Methyl-D-Aspartate Receptor: Structure-Activity Relationship Study on Steroidal C-17 and C-20 Oxime Ethers

Adla, S. K.; Krausova, B. H.; Kysilov, B.; Kudlacek, K.; Soucek, R.; Budesinsky, M.; Voldrich, J.; Vyklicky, L.; Kudova, E.

2025-10-03 neuroscience
10.1101/2025.10.03.680025 bioRxiv
Show abstract

N-methyl-D-aspartate receptors (NMDARs) are crucial therapeutic targets, modulated by endogenous neurosteroids like pregnenolone sulfate (PES). This study investigates a novel structure-activity relationship approach focusing on the steroidal D-ring, employing the bioisosteric replacement of C-17 or C-20 keto groups with oximes and oxime ethers. We synthesized a series of pregn-5-ene and androst-5-ene derivatives (11-23) and evaluated their positive allosteric modulator (PAM) activity on recombinant rat GluN1/GluN2B receptors via patch-clamp in HEK293 cells. Our study revealed that pregnenolone-derived C-20 oxime ethers are potent and efficacious PAMs of NMDAR. Several analogues have been demonstrated as more potent than PES (Emax = 116%; EC50 = 21.7 {micro}M). Compound 12 (C-20 ethyl oxime ether, C-3 hemiglutarate) displayed the highest efficacy, potentiating NMDAR currents over 6-fold more than PES (Emax = 673 {+/-} 121%; EC50 = 8.7 {+/-} 1.1 {micro}M). Compound 17 (C-20 methyl oxime ether analogue) exhibited the highest potency, being over 3.5-fold more potent than PES (Emax = 503 {+/-} 68%; EC50 = 6.1 {+/-} 0.4 {micro}M). In contrast, some C-17 analogues and derivatives with bulkier C-20 oxime substituents showed complex modulatory behavior. Promisingly, key compounds demonstrated favorable in vitro ADME profiles, including high metabolic stability and, for 12, excellent thermodynamic solubility. These results validate C-20 oxime ether modification of the pregnenolone scaffold as an effective strategy for generating potent NMDAR PAMs with potentially superior efficacy and drug-like properties compared to endogenous modulators.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
European Journal of Medicinal Chemistry
16 papers in training set
Top 0.1%
14.7%
2
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.1%
10.3%
3
eLife
5422 papers in training set
Top 8%
8.4%
4
Journal of Medicinal Chemistry
68 papers in training set
Top 0.1%
7.3%
5
Scientific Reports
3102 papers in training set
Top 16%
6.5%
6
PLOS ONE
4510 papers in training set
Top 30%
5.0%
50% of probability mass above
7
International Journal of Molecular Sciences
453 papers in training set
Top 1%
5.0%
8
ACS Omega
90 papers in training set
Top 0.3%
4.1%
9
RSC Advances
18 papers in training set
Top 0.2%
3.7%
10
ACS Chemical Neuroscience
60 papers in training set
Top 0.6%
3.1%
11
Frontiers in Chemistry
14 papers in training set
Top 0.1%
2.1%
12
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.3%
1.9%
13
Molecules
37 papers in training set
Top 0.9%
1.5%
14
Pharmaceuticals
33 papers in training set
Top 0.9%
1.4%
15
Heliyon
146 papers in training set
Top 5%
0.9%
16
Pharmacology Research & Perspectives
11 papers in training set
Top 0.2%
0.9%
17
Journal of Biological Chemistry
641 papers in training set
Top 4%
0.8%
18
JACS Au
35 papers in training set
Top 1%
0.8%
19
Bioorganic & Medicinal Chemistry Letters
10 papers in training set
Top 0.3%
0.8%
20
Pharmacological Research
15 papers in training set
Top 0.2%
0.8%
21
NeuroImage
813 papers in training set
Top 6%
0.7%
22
Brain Research
35 papers in training set
Top 2%
0.7%
23
Open Biology
95 papers in training set
Top 3%
0.7%
24
ACS Bio & Med Chem Au
11 papers in training set
Top 0.2%
0.5%
25
ACS Pharmacology & Translational Science
40 papers in training set
Top 1%
0.5%
26
Journal of Natural Products
11 papers in training set
Top 0.4%
0.5%
27
Journal of Infection and Public Health
15 papers in training set
Top 1%
0.5%
28
iScience
1063 papers in training set
Top 40%
0.5%
29
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 12%
0.5%